Results 131 to 140 of about 852 (150)

Dramatic response to Evinacumab in a North Indian girl with homozygous familial hypercholesterolemia

Journal of Pediatric Endocrinology and Metabolism
Abstract Objectives Homozygous familial hypercholesterolemia (HoFH) is a rare inherited disorder of lipoprotein metabolism associated with significant morbidity and early mortality. The conventional management with lipid-lowering drugs and lipoprotein apheresis is unable to consistently achieve ...
Sonali Arora, Sayan Banerjee, Arun George, Anju Bala, Shyam Kumar Singh Thingnam, Manoj Kumar Rohit, Devi Dayal   +6 more
openaire   +2 more sources

Evinacumab bei Patienten mit therapierefraktärer Hypercholesterinämie

Der Internist, 2021
Eberhard Windler, S. Nitschmann
openaire   +1 more source

Evinacumab reduces remnant cholesterol in patients with hypercholesterolemia or hypertriglyceridemia

Atherosclerosis, 2022
R.S. Rosenson, D. Rader, S. Ali, P. Banerjee, J. Mcginniss, R. Pordy   +5 more
openaire   +1 more source

Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia

Journal of Clinical Medicine, 2023
, Stanisław Surma
exaly  

Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia?

Expert Opinion on Biological Therapy, 2021

exaly  

Evinacumab reduces EU apheresis eligibility in patients with homozygous familial hypercholesterolemia

Atherosclerosis, 2023
Fredrick J Raal, Jennifer McGinniss, Robert Pordy, Richard T Georga, Poulabi Banerjee, Jian Zhai, Shazia Ali, Patrick M Moriarty, Robert S Rosenson   +8 more
openaire   +1 more source

Evinacumab y lomitapida en hipercolesterolemia familiar homocigótica

Panorama Actual del Medicamento
Evinacumab y lomitapida constituyen dos nuevas opciones de tratamiento hipolipemiante para pacientes con hipercolesterolemia familiar homocigótica (HFHo). El primero es un anticuerpo monoclonal que se une de forma específica a la proteína ANGPTL3, neutralizando su actividad y reduciendo así de forma indirecta los niveles tanto de triglicéridos como de ...
openaire   +1 more source

Refractory Hypercholesterolemia in Heterozygous Familial Hypercholesterolemia Treated with Evinacumab

Journal of Clinical Lipidology, 2023
Tiffany Haynes, Laura Grace Kukuc, Robert Fishberg   +2 more
openaire   +1 more source

A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects

Atherosclerosis, 2020
Vladimir Son, Alberico Luigi Catapano, Mariko Harada-Shiba   +2 more
exaly  

[Evinacumab in patients with treatment-refractory hypercholesterolemia].

Der Internist, 2021
Eberhard, Windler, S, Nitschmann
openaire   +1 more source